

6 BIBLIOGRAPHY

- Adams, L.S. et al. (2010) ‘Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway’, *Cancer research*, 70(9), pp. 3594–3605. Available at: <https://doi.org/10.1158/0008-5472.CAN-09-3565>.
- Afify, S.M. and Seno, M. (2019) ‘Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation’, *Cancers*, 11(3). Available at: <https://doi.org/10.3390/CANCERS11030345>.
- Agrogiannis, G.D. et al. (2014) ‘Insulin-like growth factors in embryonic and fetal growth and skeletal development (Review)’, *Molecular medicine reports*, 10(2), pp. 579–584. Available at: <https://doi.org/10.3892/MMR.2014.2258>.
- Ahmadi, S.E. et al. (2021) ‘MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies’, *Journal of hematology & oncology*, 14(1). Available at: <https://doi.org/10.1186/S13045-021-01111-4>.
- Aleem, E. et al. (2011) ‘Upregulation of the insulin receptor and type i insulin-like growth factor receptor are early events in hepatocarcinogenesis’, *Toxicologic Pathology*, 39(3), pp. 524–543. Available at: <https://doi.org/10.1177/0192623310396905>.
- Allard, J.B. and Duan, C. (2018) ‘IGF-binding proteins: Why do they exist and why are there so many?’, *Frontiers in Endocrinology*, 9(APR), p. 117. Available at: <https://doi.org/10.3389/FENDO.2018.00117/XML/NLM>.
- Ambros, P. et al. (no date) ‘International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee’, *nature.com* [Preprint]. Available at: <https://www.nature.com/articles/6605014> (Accessed: 25 August 2022).
- Aravindan, N. et al. (2019) ‘MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution’, *Cancer Drug Resistance*, 2(4), p. 1086. Available at: <https://doi.org/10.20517/CDR.2019.68>.
- Au-Yeung, G. et al. (2017) ‘Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition’, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 23(7), pp. 1862–1874. Available at: <https://doi.org/10.1158/1078-0432.CCR-16-0620>.
- Ayob, A.Z. and Ramasamy, T.S. (2018) ‘Cancer stem cells as key drivers of tumour progression’, *Journal of Biomedical Science* 2018 25:1, 25(1), pp. 1–18. Available at: <https://doi.org/10.1186/S12929-018-0426-4>.

Azarova, A.M., Gautam, G. and George, R.E. (2011) ‘Emerging importance of ALK in neuroblastoma’, *Seminars in cancer biology*, 21(4), pp. 267–275. Available at: <https://doi.org/10.1016/J.SEMCANCER.2011.09.005>.

Aziz, F. et al. (2022) ‘Relevance of miR-223 as Potential Diagnostic and Prognostic Markers in Cancer’, *Biology*, 11(2). Available at: <https://doi.org/10.3390/BIOLOGY11020249>.

Baas, P. et al. (2021) ‘First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial’, *The Lancet*, 397(10272), pp. 375–386. Available at: [https://doi.org/10.1016/S0140-6736\(20\)32714-8](https://doi.org/10.1016/S0140-6736(20)32714-8).

Bach, L.A. (2018) ‘IGF-binding proteins’, *Journal of molecular endocrinology*, 61(1), pp. T11–T28. Available at: <https://doi.org/10.1530/JME-17-0254>.

Bachelder, R.E. et al. (2005) ‘Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition’, *The Journal of cell biology*, 168(1), pp. 29–33. Available at: <https://doi.org/10.1083/JCB.200409067>.

Bao, X.H. et al. (2010) ‘IGF-IR and its inhibitors in gastrointestinal carcinomas’, *Oncology Letters*, 1(1), pp. 195–201. Available at: https://doi.org/10.3892/OL_00000036/ABSTRACT.

Bauer, J. et al. (2015) ‘Activin and TGF β use diverging mitogenic signaling in advanced colon cancer’, *Molecular Cancer*, 14(1). Available at: <https://doi.org/10.1186/S12943-015-0456-4>.

Berlanga, P., Cañete, A. and Castel, V. (2017) ‘Advances in emerging drugs for the treatment of neuroblastoma’, *Expert opinion on emerging drugs*, 22(1), pp. 63–75. Available at: <https://doi.org/10.1080/14728214.2017.1294159>.

Berthold, R. et al. (2022) ‘Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.’, *Oncogenesis*, 11(1), pp. 20–20. Available at: <https://doi.org/10.1038/S41389-022-00394-7>.

Bray, I. et al. (2009) ‘Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival’, *PloS one*, 4(11). Available at: <https://doi.org/10.1371/JOURNAL.PONE.0007850>.

Calao, M. et al. (2012) ‘Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation’, *Oncogene* 2013 32:31, 32(31), pp. 3616–3626. Available at: <https://doi.org/10.1038/onc.2012.368>.

Calin, G.A. et al. (2002a) ‘Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia’, *Proceedings of the National Academy of Sciences of the United States of America*, 99(24), pp. 15524–15529. Available at: <https://doi.org/10.1073/PNAS.242606799>.

Calin, G.A. et al. (2002b) ‘Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia’, *Proceedings of the National Academy of Sciences of the United States of America*, 99(24), pp. 15524–15529. Available at: <https://doi.org/10.1073/PNAS.242606799>.

Cao, J. and Yee, D. (2021) ‘Disrupting Insulin and IGF Receptor Function in Cancer’, *International journal of molecular sciences*, 22(2), pp. 1–13. Available at: <https://doi.org/10.3390/IJMS22020555>.

Carrasco-Garcia, E. et al. (2018) ‘PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines’, *Cells*, 7(9), p. 131. Available at: <https://doi.org/10.3390/CELLS7090131>.

Carthew, R.W. and Sontheimer, E.J. (2009) ‘Origins and Mechanisms of miRNAs and siRNAs’, *Cell*, 136(4), pp. 642–655. Available at: <https://doi.org/10.1016/J.CELL.2009.01.035>.

Castel, V. et al. (2001) ‘Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results’, *Medical and pediatric oncology*, 37(6), pp. 537–542. Available at: <https://doi.org/10.1002/MPO.1248>.

Catalanotto, C., Cogoni, C. and Zardo, G. (2016) ‘MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions’, *International journal of molecular sciences*, 17(10). Available at: <https://doi.org/10.3390/IJMS17101712>.

Catellani, C. et al. (2021) ‘GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer’, *Frontiers in Endocrinology*, 12. Available at: <https://doi.org/10.3389/FENDO.2021.701246>.

Chang, T.S. et al. (2015) ‘Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression’, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 21(1), pp. 201–210. Available at: <https://doi.org/10.1158/1078-0432.CCR-13-3274>.

Chang, W.W. et al. (2013) ‘The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors’, *Breast cancer research : BCR*, 15(3). Available at: <https://doi.org/10.1186/BCR3423>.

Chen, P.C. et al. (2021) ‘Niche Modulation of IGF-1R Signaling: Its Role in Stem Cell Pluripotency, Cancer Reprogramming, and Therapeutic Applications’, *Frontiers in Cell and Developmental Biology*, 8, p. 1780. Available at: <https://doi.org/10.3389/FCELL.2020.625943/XML/NLM>.

Chen, Y. and Stallings, R.L. (2007) ‘Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis’, *Cancer research*, 67(3), pp. 976–983. Available at: <https://doi.org/10.1158/0008-5472.CAN-06-3667>.

Chen, Z. et al. (2009) ‘Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo’, *Neoplasia (New York, N.Y.)*, 11(8), p. 753. Available at: <https://doi.org/10.1593/NEO.09466>.

Ching, R.H.H. et al. (2017) ‘C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/ Nanog signaling pathway’, *Oncotarget*, 8(14), pp. 23507–23516. Available at: <https://doi.org/10.18632/ONCOTARGET.15183>.

Choudhari, A.S. et al. (2019) ‘Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice’, *Frontiers in Pharmacology*, 10. Available at: <https://doi.org/10.3389/FPHAR.2019.01614>.

- Clemons, D.R. (2007) ‘Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer’, *Nature reviews. Drug discovery*, 6(10), pp. 821–833. Available at: <https://doi.org/10.1038/NRD2359>.
- Cooper, G.M. (2000) ‘The Development and Causes of Cancer’. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK9963/> (Accessed: 24 August 2022).
- Coughlan, D. et al. (2017) ‘Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States’, *Pediatric hematology and oncology*, 34(5), pp. 320–330. Available at: <https://doi.org/10.1080/08880018.2017.1373315>.
- Dallas, N.A. et al. (2009) ‘Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition’, *Cancer research*, 69(5), pp. 1951–1957. Available at: <https://doi.org/10.1158/0008-5472.CAN-08-2023>.
- Das, S. et al. (2013) ‘Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs’, *Oncogene*, 32(24), pp. 2927–2936. Available at: <https://doi.org/10.1038/ONC.2012.311>.
- Davaadelger, B. et al. (2016) ‘Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor’, *Oncotarget*, 7(19), pp. 27511–27526. Available at: <https://doi.org/10.18632/ONCOTARGET.8484>.
- Deng, Q.P. et al. (2017) ‘Effects of Glycyrrhizin in a Mouse Model of Lung Adenocarcinoma’, *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 41(4), pp. 1383–1392. Available at: <https://doi.org/10.1159/000467897>.
- Derksen, P.W.B. et al. (2006) ‘Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis’, *Cancer cell*, 10(5), pp. 437–449. Available at: <https://doi.org/10.1016/J.CCR.2006.09.013>.
- Ding, N. et al. (2020) ‘The Role of MiR-5094 as a Proliferation Suppressor during Cellular Radiation Response via Downregulating STAT5b’, *Journal of Cancer*, 11(8), p. 2222. Available at: <https://doi.org/10.7150/JCA.39679>.
- Ding, Q. et al. (2005) ‘Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin’, *Molecular cell*, 19(2), pp. 159–170. Available at: <https://doi.org/10.1016/J.MOLCEL.2005.06.009>.
- Dobre, M. et al. (2021) ‘Dysregulation of miRNAs targeting the igf-1r pathway in pancreatic ductal adenocarcinoma’, *Cells*, 10(8). Available at: <https://doi.org/10.3390/CELLS10081856/S1>.
- Dong, L., Du, M. and Lv, Q. (2019) ‘Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway’, *Acta Biochimica et Biophysica Sinica*, 51(7), pp. 753–760. Available at: <https://doi.org/10.1093/ABBS/GMZ055>.
- Dong, Z. et al. (2017) ‘Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma’, *British Journal of Cancer* 2017 116:12, 116(12), pp. 1572–1584. Available at: <https://doi.org/10.1038/bjc.2017.126>.

Dou, J. et al. (2018) ‘Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence’, *Oncotarget*, 9(28), pp. 20089–20102. Available at: <https://doi.org/10.18632/ONCOTARGET.24015>.

Duan, Z. et al. (2009) ‘Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines’, *Molecular cancer therapeutics*, 8(8), pp. 2122–2130. Available at: <https://doi.org/10.1158/1535-7163.MCT-09-0115>.

Dupont, J. et al. (2001) ‘Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor’, *The Journal of biological chemistry*, 276(28), pp. 26699–26707. Available at: <https://doi.org/10.1074/JBC.M102664200>.

El-Badry, O.M. et al. (1989) ‘Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II.’, *Journal of Clinical Investigation*, 84(3), p. 829. Available at: <https://doi.org/10.1172/JCI114243>.

Esquela-Kerscher, A. and Slack, F.J. (2006) ‘Oncomirs - microRNAs with a role in cancer’, *Nature reviews. Cancer*, 6(4), pp. 259–269. Available at: <https://doi.org/10.1038/NRC1840>.

Ferlay, J. et al. (2021) ‘Cancer statistics for the year 2020: An overview’, *International journal of cancer*, 149(4), pp. 778–789. Available at: <https://doi.org/10.1002/IJC.33588>.

Forbes, B.E., McCarthy, P. and Norton, R.S. (2012) ‘Insulin-Like Growth Factor Binding Proteins: A Structural Perspective’, *Frontiers in Endocrinology*, 3(MAR). Available at: <https://doi.org/10.3389/FENDO.2012.00038>.

Fourest-Lievin, A. et al. (2006) ‘Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1’, *Molecular biology of the cell*, 17(3), pp. 1041–1050. Available at: <https://doi.org/10.1091/MBC.E05-07-0621>.

Gantier, M.P., Sadler, A.J. and Williams, B.R.G. (2007) ‘Fine-tuning of the innate immune response by microRNAs’, *Immunology and cell biology*, 85(6), pp. 458–462. Available at: <https://doi.org/10.1038/SJ.ICB.7100091>.

George, B. et al. (2019) ‘Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma’, *Journal of Hematology and Oncology*, 12(1), pp. 1–15. Available at: <https://doi.org/10.1186/S13045-019-0768-8/FIGURES/7>.

Gérard, C., Lemaigre, F. and Gonze, D. (2019) ‘Modeling the Dynamics of Let-7-Coupled Gene Regulatory Networks Linking Cell Proliferation to Malignant Transformation’, *Frontiers in Physiology*, 10. Available at: <https://doi.org/10.3389/FPHYS.2019.00848/FULL>.

Ghosh, S. and Karin, M. (2002) ‘Missing pieces in the NF-κB puzzle’, *Cell*, 109(2 SUPPL. 1). Available at: [https://doi.org/10.1016/S0092-8674\(02\)00703-1](https://doi.org/10.1016/S0092-8674(02)00703-1).

Gilan, O. et al. (2020) ‘Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation’, *Science (New York, N.Y.)*, 368(6489), pp. 387–394. Available at: <https://doi.org/10.1126/SCIENCE.AAZ8455>.

Girnita, A. et al. (2004a) ‘Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth’, *Cancer research*, 64(1), pp. 236–242. Available at: <https://doi.org/10.1158/0008-5472.CAN-03-2522>.

Girnita, A. et al. (2004b) ‘Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth’, *Cancer research*, 64(1), pp. 236–242. Available at: <https://doi.org/10.1158/0008-5472.CAN-03-2522>.

Girnita, A. et al. (2004c) ‘Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth’, *Cancer Research*, 64(1), pp. 236–242. Available at: <https://doi.org/10.1158/0008-5472.CAN-03-2522>.

Girnita, A. et al. (2008) ‘The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells’, *Acta Ophthalmologica*, 86(thesis4), pp. 26–34. Available at: <https://doi.org/10.1111/J.1755-3768.2008.01183.X>.

Girnita, L. et al. (2014) ‘Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation’, *Cellular and molecular life sciences : CMLS*, 71(13), pp. 2403–2427. Available at: <https://doi.org/10.1007/S00018-013-1514-Y>.

van Golen, C.M. et al. (2006) ‘Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone’, *Cancer research*, 66(13), pp. 6570–6578. Available at: <https://doi.org/10.1158/0008-5472.CAN-05-1448>.

Gottardo, F. et al. (2007) ‘Micro-RNA profiling in kidney and bladder cancers’, *Urologic Oncology: Seminars and Original Investigations*, 25(5), pp. 387–392. Available at: <https://doi.org/10.1016/J.UROLONC.2007.01.019>.

Graham, T.R. et al. (2008) ‘Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells’, *Cancer research*, 68(7), pp. 2479–2488. Available at: <https://doi.org/10.1158/0008-5472.CAN-07-2559>.

Greco, S.J. and Rameshwar, P. (2007) ‘MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells’, *Proceedings of the National Academy of Sciences of the United States of America*, 104(39), pp. 15484–15489. Available at: <https://doi.org/10.1073/PNAS.0703037104>.

Grizzi, F. and Chiriva-Internati, M. (2006) ‘Cancer: Looking for simplicity and finding complexity’, *Cancer Cell International*, 6(1), pp. 1–7. Available at: <https://doi.org/10.1186/1475-2867-6-4/FIGURES/3>.

Guenther, L.M. et al. (2019) ‘A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma’, *Clinical Cancer Research*, 25(4), pp. 1343–1357. Available at: <https://doi.org/10.1158/1078-0432.CCR-18-0372/72965/AM/A-COMBINATION-CDK4-6-AND-IGF1R-INHIBITOR-STRATEGY>.

Guttridge, D.C. et al. (1999) ‘NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1’, *Molecular and Cellular Biology*, 19(8), pp. 5785–5799. Available at: <https://doi.org/10.1128/MCB.19.8.5785/ASSET/632CDD5B-41E3-4D8C-AAC3-F7EE685613C3/ASSETS/GRAPHIC/MB0890097012.JPG>.

Hall, B. and Ekanayake, S. (1991) ‘Effects of growth factors on the differentiation of neural crest cells and neural crest cell-derivatives.’, undefined [Preprint]. Available at: <https://doi.org/10.1387/IJDB.1801864>.

- Hanahan, D. and Weinberg, R.A. (2011) ‘Hallmarks of cancer: the next generation’, *Cell*, 144(5), pp. 646–674. Available at: <https://doi.org/10.1016/J.CELL.2011.02.013>.
- Hayashita, Y. et al. (2005) ‘A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation’, *Cancer research*, 65(21), pp. 9628–9632. Available at: <https://doi.org/10.1158/0008-5472.CAN-05-2352>.
- He, Q. et al. (2020) ‘IGF-IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway’, *Oncology Reports*, 44(3), p. 1094. Available at: <https://doi.org/10.3892/OR.2020.7652>.
- Hill, M. and Tran, N. (2021) ‘miRNA interplay: mechanisms and consequences in cancer’, *Disease models & mechanisms*, 14(4). Available at: <https://doi.org/10.1242/DMM.047662>.
- Hosseini, S.A., Zand, H. and Cheraghpour, M. (2019) ‘The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemosensitive Colorectal Cancer Cells’, *Medicina*, 55(4). Available at: <https://doi.org/10.3390/MEDICINA55040090>.
- Hua, H. et al. (2020) ‘Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy’, *Journal of Hematology & Oncology*, 13(1). Available at: <https://doi.org/10.1186/S13045-020-00904-3>.
- Hua, H. et al. (2021) ‘Targeting Akt in cancer for precision therapy’, *Journal of Hematology & Oncology* 2021 14:1, 14(1), pp. 1–25. Available at: <https://doi.org/10.1186/S13045-021-01137-8>.
- Huang, M. and Weiss, W.A. (2013) ‘Neuroblastoma and MYCN’, *Cold Spring Harbor Perspectives in Medicine*, 3(10). Available at: <https://doi.org/10.1101/CSHPERSPECT.A014415>.
- Ianza, A. et al. (2021) ‘Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer’, *Frontiers in Cell and Developmental Biology*, 9, p. 641449. Available at: <https://doi.org/10.3389/FCELL.2021.641449>.
- Iwasaki, T. et al. (2015) ‘Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells’, *International Journal of Oncology*, 46(4), pp. 1543–1550. Available at: <https://doi.org/10.3892/IJO.2015.2867/HTML>.
- Jana, A. et al. (2017) ‘NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway’, *Oncotarget*, 8(23), p. 37377. Available at: <https://doi.org/10.18632/ONCOTARGET.16343>.
- Janoueix-Lerosey, I. et al. (2008) ‘Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma’, *Nature*, 455(7215), pp. 967–970. Available at: <https://doi.org/10.1038/NATURE07398>.
- Jansson, M.D. and Lund, A.H. (2012) ‘MicroRNA and cancer’, *Molecular Oncology*, 6(6), pp. 590–610. Available at: <https://doi.org/10.1016/J.MOLONC.2012.09.006>.
- Jia, C.Y. et al. (2011) ‘MiR-223 Suppresses Cell Proliferation by Targeting IGF-1R’, *PLoS ONE*, 6(11). Available at: <https://doi.org/10.1371/JOURNAL.PONE.0027008>.

Johnsen, J.I. et al. (2018) ‘Molecular mechanisms and therapeutic targets in neuroblastoma’, Pharmacological research, 131, pp. 164–176. Available at: <https://doi.org/10.1016/J.PHRS.2018.02.023>.

Johnsen, J.I., Dyberg, C. and Wickström, M. (2019) ‘Neuroblastoma—A Neural Crest Derived Embryonal Malignancy’, Frontiers in Molecular Neuroscience, 12. Available at: <https://doi.org/10.3389/FNMOL.2019.00009>.

Johnson, S.M. et al. (2005) ‘RAS is regulated by the let-7 microRNA family’, Cell, 120(5), pp. 635–647. Available at: <https://doi.org/10.1016/J.CELL.2005.01.014>.

Jones, J.I. and Clemons, D.R. (1995) ‘Insulin-like growth factors and their binding proteins: biological actions’, Endocrine reviews, 16(1), pp. 3–34. Available at: <https://doi.org/10.1210/EDRV-16-1-3>.

Jopling, C.L. et al. (2005) ‘Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA’, Science (New York, N.Y.), 309(5740), pp. 1577–1581. Available at: <https://doi.org/10.1126/SCIENCE.1113329>.

Kaplan, S.A. and Cohen, P. (2007) ‘The somatomedin hypothesis 2007: 50 years later’, The Journal of clinical endocrinology and metabolism, 92(12), pp. 4529–4535. Available at: <https://doi.org/10.1210/JC.2007-0526>.

Kaszak, I. et al. (2020) ‘Role of Cadherins in Cancer-A Review’, International journal of molecular sciences, 21(20), pp. 1–17. Available at: <https://doi.org/10.3390/IJMS21207624>.

Kelleher, F.C. (2013) ‘Close Neighbours on Chromosome 2 the ALK and MYCN Genes. Implications for Targeted Therapeutics in Neuroblastoma’, undefined [Preprint]. Available at: <https://doi.org/10.5772/55300>.

Kim, H.-J. et al. (2007) ‘Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail’, Molecular and cellular biology, 27(8), pp. 3165–3175. Available at: <https://doi.org/10.1128/MCB.01315-06>.

Kohlmeyer, J.L. et al. (2020) ‘CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets’, International Journal of Molecular Sciences, 21(8). Available at: <https://doi.org/10.3390/IJMS21083018>.

Kong, L.R. et al. (2020) ‘Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation’, Nature communications, 11(1). Available at: <https://doi.org/10.1038/S41467-020-15608-Y>.

Krystal, J., Sokol, E. and Bagatell, R. (2022) ‘Neuroblastoma’, Lanzkowsky’s Manual of Pediatric Hematology and Oncology, pp. 507–523. Available at: <https://doi.org/10.1016/B978-0-12-821671-2.00035-0>.

L’Abbate, A. et al. (2014) ‘Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer’, Nucleic Acids Research, 42(14), p. 9131. Available at: <https://doi.org/10.1093/NAR/GKU590>.

Laios, A. et al. (2008a) ‘Potential role of miR-9 and miR-223 in recurrent ovarian cancer’, Molecular Cancer, 7(1), pp. 1–14. Available at: <https://doi.org/10.1186/1476-4598-7-35/FIGURES/9>.

Laios, A. et al. (2008b) ‘Potential role of miR-9 and miR-223 in recurrent ovarian cancer’, Molecular Cancer, 7(1), pp. 1–14. Available at: <https://doi.org/10.1186/1476-4598-7-35/FIGURES/9>.

Langer, C.J. et al. (2014) ‘Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer’, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), pp. 2059–2066. Available at: <https://doi.org/10.1200/JCO.2013.54.4932>.

Laviola, L., Natalicchio, A. and Giorgino, F. (2007) ‘The IGF-I signaling pathway’, Current pharmaceutical design, 13(7), pp. 663–669. Available at: <https://doi.org/10.2174/138161207780249146>.

Lee, C.H. et al. (2007) ‘NF-kappaB as a potential molecular target for cancer therapy’, BioFactors (Oxford, England), 29(1), pp. 19–35. Available at: <https://doi.org/10.1002/BIOF.5520290103>.

Lee, S.O. et al. (2021) ‘Picropodophyllotoxin Induces G1 Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer Cells via ROS Generation and Activation of p38 MAPK Signaling Pathway’, Journal of microbiology and biotechnology, 31(12), pp. 1615–1623. Available at: <https://doi.org/10.4014/JMB.2109.09012>.

Lee, W.L., Huang, J.Y. and Shyur, L.F. (2013) ‘Phytoagents for cancer management: regulation of nucleic acid oxidation, ROS, and related mechanisms’, Oxidative medicine and cellular longevity, 2013. Available at: <https://doi.org/10.1155/2013/925804>.

van Leeuwen, I.M.M. et al. (2011) ‘Mechanism-specific signatures for small-molecule p53 activators’, Cell cycle (Georgetown, Tex.), 10(10), pp. 1590–1598. Available at: <https://doi.org/10.4161/CC.10.10.15519>.

Lehman, H.L. et al. (2018) ‘NFkB hyperactivation causes invasion of esophageal squamous cell carcinoma with EGFR overexpression and p120-catenin down-regulation’, Oncotarget, 9(13), p. 11180. Available at: <https://doi.org/10.18632/ONCOTARGET.24358>.

Li, H. et al. (2014) ‘Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells’, Molecular cancer, 13(1). Available at: <https://doi.org/10.1186/1476-4598-13-136>.

Li, H. et al. (2015) ‘Insulin-like growth factor-I induces epithelial to mesenchymal transition via GSK-3 β and ZEB2 in the BGC-823 gastric cancer cell line’, Oncology letters, 9(1), pp. 143–148. Available at: <https://doi.org/10.3892/OL.2014.2687>.

Li, H. et al. (2017) ‘IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights’, Molecular Cancer, 16(1). Available at: <https://doi.org/10.1186/S12943-016-0576-5>.

Li, Z. et al. (2018) ‘IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells’, *Cell Cycle*, 17(10), p. 1212. Available at: <https://doi.org/10.1080/15384101.2018.1469873>.

Lim, S. and Kaldis, P. (2013) ‘Cdks, cyclins and CKIs: roles beyond cell cycle regulation’, *Development* (Cambridge, England), 140(15), pp. 3079–3093. Available at: <https://doi.org/10.1242/DEV.091744>.

Lin, K.S. et al. (2021) ‘Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood’, *Translational Oncology*, 14(8). Available at: <https://doi.org/10.1016/J.TRANON.2021.101019>.

Liu, J. (2018) ‘The dualistic origin of human tumors’, *Seminars in cancer biology*, 53, p. 1. Available at: <https://doi.org/10.1016/J.SEMCANCER.2018.07.004>.

Livak, K.J. and Schmittgen, T.D. (2001) ‘Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method’, *Methods* (San Diego, Calif.), 25(4), pp. 402–408. Available at: <https://doi.org/10.1006/METH.2001.1262>.

London, W.B. et al. (2005) ‘Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group’, *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 23(27), pp. 6459–6465. Available at: <https://doi.org/10.1200/JCO.2005.05.571>.

London, W.B. et al. (2011) ‘Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project’, *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 29(24), pp. 3286–3292. Available at: <https://doi.org/10.1200/JCO.2010.34.3392>.

Loria, R. et al. (2018) ‘HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance’, *Oncogene*, 37(45), p. 5926. Available at: <https://doi.org/10.1038/S41388-018-0394-X>.

Louis, C.U. and Shohet, J.M. (2015) ‘Neuroblastoma: Molecular Pathogenesis and Therapy’, <https://doi.org/10.1146/annurev-med-011514-023121>, 66, pp. 49–63. Available at: <https://doi.org/10.1146/ANNUREV-MED-011514-023121>.

Lundberg, K.I., Treis, D. and Johnsen, J.I. (2022) ‘Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies’, *Current Oncology Reports*, 24(8), p. 1053. Available at: <https://doi.org/10.1007/S11912-022-01270-8>.

Ma, J. et al. (2010a) ‘IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells’, *The Journal of surgical research*, 160(1), pp. 90–101. Available at: <https://doi.org/10.1016/J.JSS.2008.08.016>.

Ma, J. et al. (2010b) ‘IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells’, *The Journal of surgical research*, 160(1), pp. 90–101. Available at: <https://doi.org/10.1016/J.JSS.2008.08.016>.

Ma, J. bin et al. (2020) ‘KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1’, *Cell Death & Disease* 2020 11:6, 11(6), pp. 1–14. Available at: <https://doi.org/10.1038/s41419-020-2671-1>.

Ma, L. et al. (2010) ‘miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis’, *Nature Cell Biology* 2010 12:3, 12(3), pp. 247–256. Available at: <https://doi.org/10.1038/ncb2024>.

Ma, Y. et al. (2010) ‘The relationship between early embryo development and tumourigenesis’, *Journal of Cellular and Molecular Medicine*, 14(12), pp. 2697–2701. Available at: <https://doi.org/10.1111/J.1582-4934.2010.01191.X>.

Mancarella, C., Morrione, A. and Scotlandi, K. (2021) ‘Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options’, *Cells*, 10(8). Available at: <https://doi.org/10.3390/CELLS10082075>.

Marshall, G.M. et al. (2014) ‘The prenatal origins of cancer’, *Nature Reviews Cancer* 2014 14:4, 14(4), pp. 277–289. Available at: <https://doi.org/10.1038/nrc3679>.

Matthay, K.K. et al. (2016) ‘Neuroblastoma’, *Nature reviews. Disease primers*, 2. Available at: <https://doi.org/10.1038/NRDP.2016.78>.

Medema, R.H. and Lindqvist, A. (2011) ‘Boosting and suppressing mitotic phosphorylation’, *Trends in biochemical sciences*, 36(11), pp. 578–584. Available at: <https://doi.org/10.1016/J.TIBS.2011.08.006>.

Meng, X.M. et al. (2012) ‘Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro’, *Kidney international*, 81(3), pp. 266–279. Available at: <https://doi.org/10.1038/KI.2011.327>.

Menu, E. et al. (2006a) ‘Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model’, *Blood*, 107(2), pp. 655–660. Available at: <https://doi.org/10.1182/BLOOD-2005-01-0293>.

Menu, E. et al. (2006b) ‘Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model’, *Blood*, 107(2), pp. 655–660. Available at: <https://doi.org/10.1182/BLOOD-2005-01-0293>.

Meunier, S. and Vernos, I. (2012a) ‘Microtubule assembly during mitosis - from distinct origins to distinct functions?’, *Journal of cell science*, 125(Pt 12), pp. 2805–2814. Available at: <https://doi.org/10.1242/JCS.092429>.

Meunier, S. and Vernos, I. (2012b) ‘Microtubule assembly during mitosis - from distinct origins to distinct functions?’, *Journal of cell science*, 125(Pt 12), pp. 2805–2814. Available at: <https://doi.org/10.1242/JCS.092429>.

Mitra, A., Mishra, L. and Li, S. (2015) ‘EMT, CTCs and CSCs in tumor relapse and drug-resistance’, *Oncotarget*, 6(13), pp. 10697–10711. Available at: <https://doi.org/10.18632/ONCOTARGET.4037>.

Mueller, S. and Matthay, K.K. (2009) ‘Neuroblastoma: Biology and staging’, *Current Oncology Reports* 2009 11:6, 11(6), pp. 431–438. Available at: <https://doi.org/10.1007/S11912-009-0059-6>.

- Mullassery, D. et al. (2009) ‘Neuroblastoma: Contemporary management’, Archives of Disease in Childhood: Education and Practice Edition, 94(6), pp. 177–185. Available at: <https://doi.org/10.1136/ADC.2008.143909>.
- Navas, T.A. et al. (2006) ‘Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors’, Blood, 108(13), pp. 4170–4177. Available at: <https://doi.org/10.1182/BLOOD-2006-05-023093>.
- Nennig, S.E. and Schank, J.R. (2017) ‘The Role of NFkB in Drug Addiction: Beyond Inflammation’, Alcohol and alcoholism (Oxford, Oxfordshire), 52(2), pp. 172–179. Available at: <https://doi.org/10.1093/ALCALC/AGW098>.
- Neudauer, C.L. and McCarthy, J.B. (2003) ‘Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation’, Experimental Cell Research, 286(1), pp. 128–137. Available at: [https://doi.org/10.1016/S0014-4827\(03\)00049-1](https://doi.org/10.1016/S0014-4827(03)00049-1).
- Newman, D.J. and Cragg, G.M. (2016) ‘Natural Products as Sources of New Drugs from 1981 to 2014’, Journal of natural products, 79(3), pp. 629–661. Available at: <https://doi.org/10.1021/ACS.JNATPROD.5B01055>.
- Nian, W. et al. (2013) ‘miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2’, Oncology Letters, 6(2), pp. 359–366. Available at: <https://doi.org/10.3892/OL.2013.1375/HTML>.
- Nieto, M.A. et al. (2016) ‘EMT: 2016’, Cell, 166(1), pp. 21–45. Available at: <https://doi.org/10.1016/J.CELL.2016.06.028>.
- van der Noord, V.E. et al. (2019) ‘An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer’, Scientific reports, 9(1). Available at: <https://doi.org/10.1038/S41598-019-49809-3>.
- Nussbaumer, S. et al. (2011) ‘Analysis of anticancer drugs: a review’, Talanta, 85(5), pp. 2265–2289. Available at: <https://doi.org/10.1016/J.TALANTA.2011.08.034>.
- O’Donnell, K.A. et al. (2005) ‘c-Myc-regulated microRNAs modulate E2F1 expression’, Nature, 435(7043), pp. 839–843. Available at: <https://doi.org/10.1038/NATURE03677>.
- Osher, E. and Macaulay, V.M. (2019) ‘Therapeutic Targeting of the IGF Axis’, Cells, 8(8). Available at: <https://doi.org/10.3390/CELLS8080895>.
- Otte, J. et al. (2021) ‘MYCN Function in Neuroblastoma Development’, Frontiers in Oncology, 10, p. 3210. Available at: <https://doi.org/10.3389/FONC.2020.624079/XML/NLM>.
- Park, B.C., Kido, Y. and Accili, D. (1999) ‘Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes’, Biochemistry, 38(23), pp. 7517–7523. Available at: <https://doi.org/10.1021/BI9830718>.
- Park, J.R. et al. (2013) ‘Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma’, Pediatric blood & cancer, 60(6), pp. 985–993. Available at: <https://doi.org/10.1002/PBC.24433>.

- Park, J.R., Eggert, A. and Caron, H. (2010) ‘Neuroblastoma: biology, prognosis, and treatment’, Hematology/oncology clinics of North America, 24(1), pp. 65–86. Available at: <https://doi.org/10.1016/J.HOC.2009.11.011>.
- Patterson, J.O. et al. (2021) ‘Cdk control pathways integrate cell size and ploidy information to control cell division’, eLife, 10. Available at: <https://doi.org/10.7554/ELIFE.64592>.
- Paul, M. et al. (2019) ‘Bisdemethoxycurcumin promotes apoptosis in human platelets via activation of ERK signaling pathway.’, Toxicology in Vitro : an International Journal Published in Association with BIBRA, 63, pp. 104743–104743. Available at: <https://doi.org/10.1016/J.TIV.2019.104743>.
- Pearson, A.D. et al. (2008) ‘High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial’, The Lancet. Oncology, 9(3), pp. 247–256. Available at: [https://doi.org/10.1016/S1470-2045\(08\)70069-X](https://doi.org/10.1016/S1470-2045(08)70069-X).
- Petric, R.C. et al. (2015) ‘Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers’, OncoTargets and therapy, 8, pp. 2053–2066. Available at: <https://doi.org/10.2147/OTT.S83597>.
- Pierce, G.B. (1983) ‘The cancer cell and its control by the embryo. Rous-Whipple Award lecture.’, The American Journal of Pathology, 113(1), p. 117. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1916304/> (Accessed: 24 August 2022).
- Pinto, N.R. et al. (2015) ‘Advances in Risk Classification and Treatment Strategies for Neuroblastoma’, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(27), pp. 3008–3017. Available at: <https://doi.org/10.1200/JCO.2014.59.4648>.
- Piskareva, O. and Stallings, R.L. (2015) ‘Neuroblastoma’, Epigenetic Cancer Therapy, pp. 289–316. Available at: <https://doi.org/10.1016/B978-0-12-800206-3.00013-6>.
- Pollak, M.N., Schernhammer, E.S. and Hankinson, S.E. (2004) ‘Insulin-like growth factors and neoplasia’, Nature Reviews Cancer, 4(7), pp. 505–518. Available at: <https://doi.org/10.1038/NRC1387>.
- Poy, M.N. et al. (2004) ‘A pancreatic islet-specific microRNA regulates insulin secretion’, Nature, 432(7014), pp. 226–230. Available at: <https://doi.org/10.1038/NATURE03076>.
- Prakobwong, S. et al. (2011) ‘Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways’, Carcinogenesis, 32(9), pp. 1372–1380. Available at: <https://doi.org/10.1093/CARCIN/BGR032>.
- de Preter, K. et al. (2006) ‘Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes’, Genome Biology, 7(9), p. R84. Available at: <https://doi.org/10.1186/GB-2006-7-9-R84>.
- Reya, T. et al. (2001) ‘Stem cells, cancer, and cancer stem cells’, Nature, 414(6859), pp. 105–111. Available at: <https://doi.org/10.1038/35102167>.
- RL, S. (2009) ‘MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics’, Current pharmaceutical design, 15(4), pp. 456–462. Available at: <https://doi.org/10.2174/138161209787315837>.

- Romania, P. et al. (2012) ‘Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives’, International journal of molecular sciences, 13(12), pp. 16554–16579. Available at: <https://doi.org/10.3390/IJMS131216554>.
- Sa, G. and Das, T. (2008) ‘Anti cancer effects of curcumin: cycle of life and death’, Cell Division, 3, p. 14. Available at: <https://doi.org/10.1186/1747-1028-3-14>.
- Sabbatini, P. et al. (2009) ‘GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers’, Molecular Cancer Therapeutics, 8(10), pp. 2811–2820. Available at: <https://doi.org/10.1158/1535-7163.MCT-09-0423>.
- Schönherr, C. et al. (2012) ‘Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells’, Oncogene, 31(50), pp. 5193–5200. Available at: <https://doi.org/10.1038/ONC.2012.12>.
- Schulte, J.H. et al. (2009) ‘MicroRNAs in the pathogenesis of neuroblastoma’, Cancer letters, 274(1), pp. 10–15. Available at: <https://doi.org/10.1016/J.CANLET.2008.06.010>.
- Sears, R. et al. (2000) ‘Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability’, Genes & development, 14(19), pp. 2501–2514. Available at: <https://doi.org/10.1101/GAD.836800>.
- Shang, A. et al. (2017) ‘miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway’, <https://doi.org/10.1080/21691401.2017.1391825>, 46(8), pp. 1754–1762. Available at: <https://doi.org/10.1080/21691401.2017.1391825>.
- Shawky, A.M. et al. (2021) ‘Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents’, Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), p. 1313. Available at: <https://doi.org/10.1080/14756366.2021.1937618>.
- Shorning, B.Y. et al. (2020) ‘The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling’, International journal of molecular sciences, 21(12), pp. 1–47. Available at: <https://doi.org/10.3390/IJMS21124507>.
- Shrivastava, R. and Bhaduria, S. (2016) ‘Role of Growth Factor Signaling in Cancer’, Defence Life Science Journal, 1(1), pp. 34–47. Available at: <https://doi.org/10.14429/DLSJ.1.10059>.
- Simpson, A. et al. (2017) ‘Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies’, Targeted oncology, 12(5), pp. 571–597. Available at: <https://doi.org/10.1007/S11523-017-0514-5>.
- Škovierová, H. et al. (2018) ‘Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review)’, International journal of molecular medicine, 41(3), pp. 1187–1200. Available at: <https://doi.org/10.3892/IJMM.2017.3320>.
- Smith, V. and Foster, J. (2018) ‘High-Risk Neuroblastoma Treatment Review’, Children (Basel, Switzerland), 5(9). Available at: <https://doi.org/10.3390/CHILDREN5090114>.
- Sotiriou, C. et al. (2003) ‘Breast cancer classification and prognosis based on gene expression profiles from a population-based study’, Proceedings of the National Academy of Sciences of the

United States of America, 100(18), pp. 10393–10398. Available at: <https://doi.org/10.1073/PNAS.1732912100>.

Stivarou, T. and Patsavoudi, E. (2015) ‘Extracellular molecules involved in cancer cell invasion’, Cancers, 7(1), pp. 238–265. Available at: <https://doi.org/10.3390/CANCERS7010238>.

Strömberg, T. et al. (2006) ‘IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells’, Blood, 107(2), pp. 669–678. Available at: <https://doi.org/10.1182/BLOOD-2005-01-0306>.

Stuard, W.L., Titone, R. and Robertson, D.M. (2020) ‘The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease’, Frontiers in endocrinology, 11. Available at: <https://doi.org/10.3389/FENDO.2020.00024>.

Sun, R. et al. (2022a) ‘Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways’, Translational Lung Cancer Research, 11(4), pp. 543–559. Available at: <https://doi.org/10.21037/TLCR-21-765/COIF>.

Sun, R. et al. (2022b) ‘Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways’, Translational Lung Cancer Research, 11(4), pp. 543–559. Available at: <https://doi.org/10.21037/TLCR-21-765/COIF>.

Szewczyk, K. et al. (2019) ‘Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain’, Frontiers in Oncology, 9, p. 1018. Available at: <https://doi.org/10.3389/FONC.2019.01018/XML/NLM>.

Tanenbaum, M.E. and Medema, R.H. (2010) ‘Mechanisms of centrosome separation and bipolar spindle assembly’, Developmental cell, 19(6), pp. 797–806. Available at: <https://doi.org/10.1016/J.DEVCEL.2010.11.011>.

Tang, R. et al. (2016) ‘MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer’, Oncotarget, 7(5), p. 5972. Available at: <https://doi.org/10.18632/ONCOTARGET.6821>.

Tarnowski, M. et al. (2015) ‘5-Azacytidine inhibits human rhabdomyosarcoma cell growth by downregulating insulin-like growth factor 2 expression and reactivating the H19 gene product miR-675, which negatively affects insulin-like growth factors and insulin signaling’, International Journal of Oncology, 46(5), pp. 2241–2250. Available at: <https://doi.org/10.3892/IJO.2015.2906/HTML>.

Tarnowski, M. et al. (2017a) ‘Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo’, BMC Cancer, 17(1), pp. 1–11. Available at: <https://doi.org/10.1186/S12885-017-3495-Y/FIGURES/7>.

Tarnowski, M. et al. (2017b) ‘Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo’, BMC Cancer, 17(1), pp. 1–11. Available at: <https://doi.org/10.1186/S12885-017-3495-Y/FIGURES/7>.

Tchakarska, G. and Sola, B. (2020) ‘The double dealing of cyclin D1’, Cell cycle (Georgetown, Tex.), 19(2), pp. 163–178. Available at: <https://doi.org/10.1080/15384101.2019.1706903>.

- Teo, K. et al. (2018) ‘E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.’, *Scientific Reports*, 8(1), pp. 15454–15454. Available at: <https://doi.org/10.1038/S41598-018-33525-5>.
- Thiery, J.P. et al. (2009) ‘Epithelial-mesenchymal transitions in development and disease’, *Cell*, 139(5), pp. 871–890. Available at: <https://doi.org/10.1016/J.CELL.2009.11.007>.
- Thorpe, L.M. et al. (2017) ‘PI3K-p110 α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 α ’, *Proceedings of the National Academy of Sciences of the United States of America*, 114(27), pp. 7095–7100. Available at: <https://doi.org/10.1073/PNAS.1704706114>.
- Tsubota, S. and Kadomatsu, K. (2017) ‘Origin and mechanism of neuroblastoma.’, *Oncoscience*, 4(7–8), pp. 70–72. Available at: <https://doi.org/10.18632/ONCOSCIENCE.360>.
- Tsui, Y.M., Chan, L.K. and Ng, I.O.L. (2020) ‘Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential’, *British Journal of Cancer* 2020 122:10, 122(10), pp. 1428–1440. Available at: <https://doi.org/10.1038/s41416-020-0823-9>.
- Vasilcanu, D. et al. (2004) ‘The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway’, *Oncogene*, 23(47), pp. 7854–7862. Available at: <https://doi.org/10.1038/SJ.ONC.1208065>.
- Vasilcanu, D. et al. (2006a) ‘The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection’, *Oncogene*, 25(22), pp. 3186–3195. Available at: <https://doi.org/10.1038/SJ.ONC.1209339>.
- Vasilcanu, D. et al. (2006b) ‘The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection’, *Oncogene* 2006 25:22, 25(22), pp. 3186–3195. Available at: <https://doi.org/10.1038/sj.onc.1209339>.
- Vazquez-Martin, A. et al. (2013) ‘IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations’, *Scientific reports*, 3. Available at: <https://doi.org/10.1038/SREP02560>.
- Vella, V. et al. (2019) ‘Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection’, *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1866(11), p. 118522. Available at: <https://doi.org/10.1016/J.BBAMCR.2019.118522>.
- Velloso, C.P. (2008) ‘Regulation of muscle mass by growth hormone and IGF-I’, *British journal of pharmacology*, 154(3), pp. 557–568. Available at: <https://doi.org/10.1038/BJP.2008.153>.
- Vishwamitra, D. et al. (2011) ‘Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma’, *Haematologica*, 96(6), p. 871. Available at: <https://doi.org/10.3324/HAEMATOL.2010.031567>.
- Vishwamitra, D. et al. (2017) ‘Type I insulin-like growth factor receptor signaling in hematological malignancies’, *Oncotarget*, 8(1), p. 1814. Available at: <https://doi.org/10.18632/ONCOTARGET.12123>.

Wang, C. et al. (2019) ‘IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways’, *Cancer Biology & Therapy*, 20(3), p. 295. Available at: <https://doi.org/10.1080/15384047.2018.1529096>.

Wang, C. et al. (2020) ‘Insulin-like growth factor-I activates NF κ B and NLRP3 inflammatory signalling via ROS in cancer cells’, *Molecular and cellular probes*, 52. Available at: <https://doi.org/10.1016/J.MCP.2020.101583>.

Wang, X.H. et al. (2019) ‘IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis’, *Cancer Management and Research*, 11, p. 5459. Available at: <https://doi.org/10.2147/CMAR.S196862>.

Waraky, A., Akopyan, K., Parrow, V., Strömborg, T., Axelson, M., Abrahmsén, L., Lindqvist, A., Larsson, O. and Aleem, E. (2014) ‘Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism’, *Oncotarget*, 5(18), p. 8379. Available at: <https://doi.org/10.18632/ONCOTARGET.2292>.

Waraky, A., Akopyan, K., Parrow, V., Strömborg, T., Axelson, M., Abrahmsén, L., Lindqvist, A., Larsson, O., Aleem, E., et al. (2014) ‘Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism’, *Oncotarget*, 5(18), pp. 8379–8392. Available at: <https://doi.org/10.18632/ONCOTARGET.2292>.

Wei, S. et al. (2020) ‘Exosomal transfer of miR-15b-3p enhances tumorigenesis and malignant transformation through the DYNLT1/Caspase-3/Caspase-9 signaling pathway in gastric cancer’, *Journal of Experimental and Clinical Cancer Research*, 39(1), pp. 1–18. Available at: <https://doi.org/10.1186/S13046-019-1511-6/FIGURES/8>.

Wijesinghe, T.P. et al. (2021) ‘Innovative therapies for neuroblastoma: The surprisingly potent role of iron chelation in up-regulating metastasis and tumor suppressors and down-regulating the key oncogene, N-myc’, *Pharmacological research*, 173. Available at: <https://doi.org/10.1016/J.PHRS.2021.105889>.

Wijnhoven, B.P.L., Dinjens, W.N.M. and Pignatelli, M. (2000) ‘E-cadherin-catenin cell-cell adhesion complex and human cancer’, *The British journal of surgery*, 87(8), pp. 992–1005. Available at: <https://doi.org/10.1046/J.1365-2168.2000.01513.X>.

Worrall, C. et al. (2017) ‘Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma’, *Oncogene*, 36(23), pp. 3274–3286. Available at: <https://doi.org/10.1038/ONC.2016.472>.

Wu, Y.T. et al. (2015) ‘Picropodophyllin inhibits the growth of Ewing’s sarcoma cells through the insulin-like growth factor-1 receptor/Akt signaling pathway’, *Molecular Medicine Reports*, 12(5), pp. 7045–7050. Available at: <https://doi.org/10.3892/MMR.2015.4266/HTML>.

Xu, Y. et al. (2014) ‘Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence’, *Trends in biochemical sciences*, 39(6), pp. 268–276. Available at: <https://doi.org/10.1016/J.TIBS.2014.04.004>.

Xue, C. et al. (2021) ‘Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression’, *Signal Transduction and Targeted Therapy* 2021 6:1, 6(1), pp. 1–17. Available at: <https://doi.org/10.1038/s41392-021-00788-w>.

- Yao, X., Xie, L. and Zeng, Y. (2020) ‘MiR-9 Promotes Angiogenesis via Targeting on Sphingosine-1- Phosphate Receptor 1’, *Frontiers in Cell and Developmental Biology*, 8, p. 755. Available at: <https://doi.org/10.3389/FCELL.2020.00755/XML/NLM>.
- Yin, S. et al. (2010) ‘Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma’, *Neuro-oncology*, 12(1), pp. 19–27. Available at: <https://doi.org/10.1093/NEUONC/NOP008>.
- Yin, W. et al. (2021) ‘Cancer and stem cells’, *Experimental Biology and Medicine*, 246(16), p. 1791. Available at: <https://doi.org/10.1177/15353702211005390>.
- Yong, S.L. and Dutta, A. (2009) ‘MicroRNAs in cancer’, *Annual review of pathology*, 4, p. 199. Available at: <https://doi.org/10.1146/ANNUREV.PATHOL.4.110807.092222>.
- Zafar, A., Wang, W., Liu, G., Wang, X., et al. (2021) ‘Molecular targeting therapies for neuroblastoma: Progress and challenges’, *Medicinal Research Reviews*, 41(2), p. 961. Available at: <https://doi.org/10.1002/MED.21750>.
- Zafar, A., Wang, W., Liu, G., Xian, W., et al. (2021) ‘Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope’, *Cancer letters*, 496, pp. 16–29. Available at: <https://doi.org/10.1016/J.CANLET.2020.09.023>.
- Zha, J. and Lackner, M.R. (2010) ‘Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy’, *undefined*, 16(9), pp. 2512–2517. Available at: <https://doi.org/10.1158/1078-0432.CCR-09-2232>.
- Zhang, Q. et al. (2020) ‘lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway’, *Journal of Cellular and Molecular Medicine*, 24(14), p. 8236. Available at: <https://doi.org/10.1111/JCMM.15499>.
- Zhang, W. et al. (2017) ‘Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells’, *PloS one*, 12(6). Available at: <https://doi.org/10.1371/JOURNAL.PONE.0179672>.
- Zhang, Z. et al. (2014) ‘Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer’, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 20(17), pp. 4559–4573. Available at: <https://doi.org/10.1158/1078-0432.CCR-13-3396>.
- Zhao, G. et al. (2017) ‘Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells’, *Oncology reports*, 37(4), pp. 2277–2285. Available at: <https://doi.org/10.3892/OR.2017.5450>.
- Zhao, Z. et al. (2019) ‘Upregulation of Insulin-Like Growth Factor-1 Receptor (IGF-1R) Reverses the Inhibitory Effect of Let-7g-5p on Migration and Invasion of Nasopharyngeal Carcinoma’, *Medical science monitor : international medical journal of experimental and clinical research*, 25, pp. 5747–5756. Available at: <https://doi.org/10.12659/MSM.914555>.
- Zheng, X. et al. (2019) ‘An Autocrine IL-6/IGF-1R Loop Mediates EMT and Promotes Tumor Growth in Non-small Cell Lung Cancer’, *International Journal of Biological Sciences*, 15(9), p. 1882. Available at: <https://doi.org/10.7150/IJBS.31999>.

Zhou, B. et al. (2017) ‘Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma’, *Oncotarget*, 8(41), p. 69746. Available at: <https://doi.org/10.18632/ONCOTARGET.19261>.

Zhou, B.P. et al. (2004) ‘Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition’, *Nature cell biology*, 6(10), pp. 931–940. Available at: <https://doi.org/10.1038/NCB1173>.

Zhou, J. et al. (2015) ‘Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer’, *Oncotarget*, 6(42), pp. 44332–44345. Available at: <https://doi.org/10.18632/ONCOTARGET.6293>.

Zhou, J.J. et al. (2014) ‘Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression’, *International journal of oncology*, 44(6), pp. 2034–2040. Available at: <https://doi.org/10.3892/IJO.2014.2347>.

Zhou, Y. et al. (2016) ‘The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer’, *Oncotarget*, 7(26), pp. 40846–40859. Available at: <https://doi.org/10.18632/ONCOTARGET.8519>.

Zhu, S. et al. (2012) ‘Activated ALK collaborates with MYCN in neuroblastoma pathogenesis’, *Cancer cell*, 21(3), pp. 362–373. Available at: <https://doi.org/10.1016/J.CCR.2012.02.010>.

Zhuang, G. et al. (2012) ‘Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway’, *The EMBO Journal*, 31(17), pp. 3513–3523. Available at: <https://doi.org/10.1038/EMBOJ.2012.183>.